SOURCE: BioMedReports

BioMedReports

December 03, 2010 07:50 ET

A Closer Look at PharmAthene and Their Pending Lawsuit Against SIGA Technologies

LOS ANGELES, CA--(Marketwire - December 3, 2010) -  PharmAthene, Inc. (NYSE Amex: PIP), the biodefense company developing medical countermeasures against biological and chemical threats, has been making headlines on Wall Street after filing a breach of contract lawsuit against SIGA Technologies Inc. Their case is set to begin Jan. 3 despite the fact that SIGA tried twice to dismiss the case or portions of the case. Just days ago, the Delaware Court of Chancery issued a ruling denying in full Siga Technologies' motion for partial summary judgment. 

In play is the fact that SIGA was initially awarded a big contract through BARDA (The U.S. Biomedical Advanced Research and Development Authority) that could be worth $2.8 billion.

Who is PharmAthene and why do they feel they may be entitled to damages in their upcoming case against SIGA?

In an exclusive interview, Eric I. Richman, the President and Chief Executive Officer of PharmAthene, tells BioMedReports about his company and shares with readers some of his own perspectives of the events surrounding the high profile case that could impact share prices of both companies going forward.

In addition, Richman shares information about his company's own development pipeline and some of the upcoming catalysts that could also impact their market-cap.

The complete report is available at: http://biomedreports.com/2010120360907/closer-look-pharmathene-and-the-lawsuit-against-siga-technologies.html

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can also access that information at:

http://biomedreports.com/fda-calendar/fda-calendar.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets.

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    BioMedReports.Com
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556